RBCC Partner n3D BioSciences Unveils Top MAD Scientists
NOKOMIS, Fla. -- July 23, 2013
In a successful bid to introduce its groundbreaking 3D cell culturing
technology to a budding generation of “MAD” scientists, Rainbow Coral Corp.
(OTCBB: RBCC) partner Nano3D BioSciences (n3D) has announced the winners of an
intriguing scientific discovery competition, The MAD Scientist Contest by n3D.
The top cash prize was awarded to Hamsa Jaganathan, Ph.D., of the Methodist
Hospital Research Institute for her amazing model of a breast tumor
microenvironment, created by co-culturing breast cancer cells and fibroblasts.
Second prize went to Matthew Hogan at the University of Houston for his
creation of a functional, or beating, primary cardiac cultures in vitro.
“The winning entries illustrate how 3-D, suspended cultures constructed using
n3D technology improve data and achieve results impossible with other
cell-culturing systems,” said RBCC CEO Patrick Brown. “The MAD Scientist
Contest also served to introduce n3D's Bio-Assembler system to the young
scientists who will undoubtedly lead cellular research into the future.”
This contest is a critical piece of n3D and RBCC's strategy to build strong
interest in the Bio-Assembler among researchers across a broad spectrum of
scientific and research disciplines. The system's revolutionary functionality
allows it to produce accurate, 3D representations of in vivo tissues faster
and easier than any other existing technology.
RBCC formed a biotech subsidiary,RainbowBioSciences, to market and develop
new medical and research technology innovations to compete alongside companies
such asBristol Myers Squibb Co.(NYSE:BMY),Biogen Idec Inc.
(NASDAQ:BIIB),Abbott Laboratories(NYSE:ABT) and Amgen
Inc.(NASDAQ:AMGN).Rainbow BioSciences acquired an equity interest in n3D
earlier last year.
For more information on RBCC’s other biotech initiatives, please
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary ofRainbow Coral
Corp.(OTCBB:RBCC).The Companycontinually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies
andinnovations. For more information on our growth-oriented business
initiatives, please visitwww.RainbowBioSciences.com. For investment
information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Suchforward-looking statementsinvolve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
Press spacebar to pause and continue. Press esc to stop.